Journal
LUPUS
Volume 25, Issue 8, Pages 873-877Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0961203316645205
Keywords
Systemic lupus erythematosus; SLE; lupus nephritis; C1q; anti-C1q
Categories
Funding
- National Institutes of Health [NIH AR 43727]
- National Center for Research Resources (NCRR), a component of the NIH [UL1 RR 025005]
- NIH Roadmap for Medical Research
Ask authors/readers for more resources
C1q is the first component of the classical complement pathway. Both clinically validated in-house ELISA assays as well as commercial ELISA kits are used for detection of anti-C1q antibodies. Anti-C1q autoantibodies can be detected in a wide range of autoimmune diseases and are highly sensitive for hypocomplementemic uticarial vasculitis. In SLE, anti-C1q are strongly associated with proliferative lupus nephritis, and their absence carries a negative predictive value for development of lupus nephritis of close to 100%. Anti-C1q in combination with anti-dsDNA and low complement has the strongest serological association with renal involvement. The anti-C1q titers correlate with global disease activity scores in patients with renal involvement, and higher titers seem to precede renal flares. After the successful treatment of a renal flare, anti-C1q has the tendency to decrease or even become undetectable. The main obstacle to the inclusion of anti-C1q in the classification criteria and clinical management of SLE is the lack of standardized laboratory assays.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available